Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AZ grants 3SBio exclusive Byetta and Bydureon rights in China

Executive Summary

AstraZeneca PLC licensed 3SBio Inc. exclusive Chinese marketing rights to its diabetes products Byetta (exenatide) and Bydureon (once-weekly exenatide) (single dose tray, dual chamber pen, and auto-injector).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies